Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Jun 2021 | FROM AKERO THERAPEUTICS

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

Dec 2020 | From Akero Therapeutics

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.